Member Info for DeAar

I'm merely copying and pasting. Should go down well with a certain LTH.

Thanks for this link Oddmoney. That Edison report contains two statements that are pertinent to some posts that have been raging here for the last 24hrs. They are:
"As a reminder, in November 2022, SDC-1801’s CTA was turned down by the MHRA and Sareum has been awaiting further clarity prior to data resubmission."
And
"Safety profile of combined TYK2/JAK1 inhibitor not certain or proved yet."

He's closely followed the behaviour of wombles, c.wombles and uber c.wombles. He's pointed out the behaviour dirty dogs and sewer rats. Last night he introduced us to a new species - sealions! The in-depth explanation of their behavior was fascinating! It was appropriately placed after the 9pm watershed too. I look forward to learning more about their behavior (sealioning) in the future.

Bailiff,
Most of the name calling and petty spats start with Ahfam. Anyone with a negative viewpoint gets called names, and some highly derogatory and dehumanising ones like "dog", "it", "thing". Of course there's also "rats", "idiot", "****" and the favourite "c.womble". There is no way this should be tolerated. His posts are regularly removed because of this abuse/bad language. Other long term holders can debate and get their point across without spitting abuse, but not Ahfam.

Sneckie,
You should have called it a "death spiral". That would've got Ahfam's back up!

Fantasy Pharma hopium. And he says he's not a ramper.....

If I had a pound for every time I've seen that posted I'd be wealthier than Mr Buffett.

Because they are saying what you need to hear rather than what you want to hear.

We don't get to see your posts anymore Ahfam. They all get removed!

Square10,
If its not a real trade then how come it's included in the volume of shares traded for the day? Total volume yesterday is 497112 shares. Without that trade the volume would be 397112.

Could today be Ichor selling? Perhaps the last of their 3million odd shares?

I'm sure I'm not the only one who's annoyed by a certain thread containing a patients name popping up again and again. AFAIK, the only way to remove the thread is to report the original post. If enough of us do it, it should be removed. It does contain personal information after all.

Ripley,
Is this your list of non-genuine posters - "Best advice post IMHO from this bb since just before Christmas this one 18 days ago .
From ...WeTookPelham "Maybe don't invest based on noise on a forum?"
DeAar, chippyjo, GF123, RayPointer, WoollyBoing, lofas" ?

I think mAb deals this year will eliminate or significantly reduce the need for any fund raising. Potential deals on the validated mAbs was mentioned far too many times at the AGM for them not to be in the pipeline.

Maybe because the new Chairman started working for Scancell on the 1st February?

While listening to the AGM again yesterday it struck me how many times antibodies, validation and deals were mentioned.
Near the beginning of her presentation, Lindy said Scancell have cash runway that extends to Q1 2024 and that they need to do further deals and other things to extend beyond that. Things she said at various points in the presentation are - 1. The antibody platform had been validated by Genmab. 2. Avidimab had been validated by Covidity. 3. Potentially going to sell (license) Avidimab to other companies as a revenue generator because it could enhance a number of antibodies in the market. 4. Can generate and licence new antibodies for new targets. 5. Can license Avidimab. 6. Hoping Genmab deal is only one of the deals they can do in the future. 7. Talking to cellular (Car T) companies as we speak about iSC2811. 8. Hoping to do good licensing deals on the back of Avidimab next year.
To me is shows Scancell know exactly what they have to do to generate revenue to validate Modi and Scib and to take their own antibodies into the clinic. 2023 is going to be about generating revenue (deals) with the two validated antibody platforms. The Chairman is in place and now we just need a new CBO.

Konar,

I listened to Botski's recording of the AGM again yesterday. On Modi, Lindy said the neoadjuvant study (dosing before surgery and subsequent tumor resection) will allow them to look at the tumor and prove the mechanism of action. This will provide the data big pharma want and this is what they did in the mice studies. This will only be done towards/at the end of cohort 4 dosing, so you are correct in saying we need to be more patient as the trial is due to run into 2024.

This was in the interims - "The COVIDITY programme, focusing on the Company's novel COVID-19 vaccine candidates SCOV1 and SCOV2, recently completed dosing in South Africa and we expect to report safety and immunogenicity data in Q1 2023".

AB,
They clearly stated why in the RNS

I'm not sure the interims have been expedited. Last year they were also on the last Wednesday of January. However, for the last three years there has been another RNS within five days of the interims being released.